Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
This trial is active, not recruiting.
|Conditions||adrenocortical carcinoma, cushing's syndrome|
|Sponsor||University of Wuerzburg|
|Collaborator||Deutsche Krebshilfe e.V., Bonn (Germany)|
|Start date||September 2005|
|End date||December 2011|
|Trial size||70 participants|
|Trial identifier||NCT00457587, Wue-Immuno-ACC-83/05|
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.
|Observational model||case control|
To find reasonable antigens for a vaccination therapy in ACC
time frame: day of blood sampling
To investigate the role of tumor-induced suppression in ACC
time frame: NA, in vitro study
Male or female participants at least 18 years old.
- patients with histological proven adrenocortical carcinoma
- healthy persons as control group
- Life expectancy > 6 months
- autoimmune diseases
- severe clinical condition
|Official title||Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma|
|Principal investigator||Martin Fassnacht, MD|
Call for more information